home / stock / lvtx / lvtx quote
Last: | $2.06 |
---|---|
Change Percent: | 1.69% |
Open: | $2.04 |
Close: | $2.06 |
High: | $2.1299 |
Low: | $2.01 |
Volume: | 33,629 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.06 | $2.04 | $2.06 | $2.1299 | $2.01 | 33,629 | 07-19-2024 |
$2.075 | $2.32 | $2.075 | $2.32 | $2.001 | 71,688 | 07-18-2024 |
$2.29 | $2.17 | $2.29 | $2.39 | $2.1248 | 181,575 | 07-17-2024 |
$2.11 | $1.78 | $2.11 | $2.22 | $1.78 | 433,212 | 07-16-2024 |
$1.8 | $1.91 | $1.8 | $1.91 | $1.72 | 123,823 | 07-15-2024 |
$1.87 | $1.78 | $1.87 | $1.89 | $1.78 | 46,507 | 07-12-2024 |
$1.79 | $1.91 | $1.79 | $1.98 | $1.78 | 101,587 | 07-11-2024 |
$1.91 | $1.91 | $1.91 | $1.9472 | $1.86 | 52,251 | 07-10-2024 |
$1.89 | $1.89 | $1.89 | $1.9 | $1.8 | 29,714 | 07-09-2024 |
$1.85 | $1.97 | $1.85 | $2.0246 | $1.85 | 51,630 | 07-08-2024 |
$1.89 | $1.8 | $1.89 | $1.93 | $1.8 | 78,248 | 07-05-2024 |
$1.8 | $1.88 | $1.8 | $1.94 | $1.79 | 41,916 | 07-04-2024 |
$1.8 | $1.88 | $1.8 | $1.94 | $1.79 | 41,916 | 07-03-2024 |
$1.89 | $1.8501 | $1.89 | $2.0199 | $1.8501 | 53,151 | 07-02-2024 |
$1.87 | $1.84 | $1.87 | $2.06 | $1.83 | 18,430 | 07-01-2024 |
$1.8 | $1.95 | $1.8 | $2.06 | $1.8 | 89,709 | 06-28-2024 |
$1.88 | $1.86 | $1.88 | $2.0256 | $1.82 | 102,355 | 06-27-2024 |
$1.85 | $1.89 | $1.85 | $2.04 | $1.84 | 67,484 | 06-26-2024 |
$1.94 | $1.8701 | $1.94 | $2.11 | $1.85 | 110,675 | 06-25-2024 |
$1.87 | $1.929 | $1.87 | $1.96 | $1.8501 | 41,974 | 06-24-2024 |
News, Short Squeeze, Breakout and More Instantly...
LAVA Therapeutics N.V. Company Name:
LVTX Stock Symbol:
NASDAQ Market:
LAVA Therapeutics N.V. Website:
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody ® platform of bispecific gamma delta T cell eng...
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamm...
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1 LAVA-1266 on track for Q2 2024 IND sub...